Avita Medical (ASX:AVH) reported Friday that its first quarter loss narrowed to $0.53 per diluted share from $0.73 per diluted share a year earlier.
Analysts polled by Visible Alpha expected a loss of $0.45 per diluted share.
Total revenue for the three months ended March 31 was $18.5 million, compared with $11.1 million a year earlier. Analysts surveyed by Visible Alpha expected $20.1 million.
The company reaffirmed its full-year 2025 guidance, anticipating commercial revenue of between $100 million and $106 million, indicating a 55% to 65% growth from a year earlier.
Shares fell nearly 20% in morning trade Friday.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。